Research
Hormonal
Insulin negatively regulates the secretion of resistin and omentin, while positively regulating the secretion of adiponectin, leptin, and other adipokines, thereby influencing systemic insulin sensitivity and energy balance.
Insulin influences the hormones your fat cells release. It boosts beneficial hormones like adiponectin (which improves insulin sensitivity) and leptin (which regulates appetite), while suppressing others like resistin. This complex interplay helps maintain metabolic balance.
GoodSupportsHIGH confidence
On the other hand, insulin appears to negatively regulate two adipokines: resistin and omentin... Among the numerous adipokines with endocrine activity... some have been described to be regulated by insulin both in vivo and in vitro. Adiponectin/ACRP30 is an adipose-derived protein with insulin-sensitizing and anti-atherosclerotic properties... insulin chronically stimulates leptin storage by pre- and post-translational mechanisms.
Why this rating
Cites multiple studies showing insulin's effect on adipokine levels.
Source
Insulin and Insulin Receptors in Adipose Tissue Development
Angelo Cignarelli et al. · International Journal of Molecular Sciences · 2019
DOI 10.3390/ijms20030759
narrative_reviewCited 213×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin regulates adipose tissue development and function by activating specific insulin receptor (INSR) splice variants (INSR-A and INSR-B) and downstream signaling cascades (PI3K/AKT), which control glucose uptake, lipid storage, and adipokine secretion.Good
- Visceral adipose tissue (VAT) exhibits higher rates of insulin-stimulated glucose uptake and more rapid insulin signaling activation compared to subcutaneous adipose tissue (SAT), which may contribute to its distinct metabolic impact.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →